



(51) International Patent Classification:

C07D 207/34 (2006.01) **C07D 233/64** (2006.01)
C07D 231/12 (2006.01) **C07D 233/68** (2006.01)
C07D 231/14 (2006.01) **C07D 233/70** (2006.01)
C07D 231/16 (2006.01) **C07D 233/84** (2006.01)
C07D 231/18 (2006.01) **C07D 249/06** (2006.01)
C07D 231/54 (2006.01) **C07D 249/08** (2006.01)
C07D 231/56 (2006.01) **C07D 261/08** (2006.01)
C07D 233/61 (2006.01)

(21) International Application Number:

PCT/IB2012/050349

(22) International Filing Date:

25 January 2012 (25.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/440,578 8 February 2011 (08.02.2011) US
 61/441,044 9 February 2011 (09.02.2011) US
 61/585,834 12 January 2012 (12.01.2012) US

(71) **Applicant** (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **APNES, Gary Erik** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **DIDI-UK, Mary Theresa** [US/US]; 61 Hickory Lane, Madison, Connecticut 06443 (US). **FILIPSKI, Kevin James** [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **GUZMAN-PEREZ, Angel** [MX/US]; 20 Gilmore Road, Belmont, Massachusetts 02478 (US). **LEE, Esther Cheng Yin** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **PFEFFERKORN, Jeffrey Allen** [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **STEVENS,**

Benjamin Dawson [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **TU, Meihua Mike** [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US).

(74) **Agent:** **KLEIMAN, Gabriel L.**; PFIZER INC. 235 East 42nd Street, New York, New York 10017 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** GLUCAGON RECEPTOR MODULATOR



(I)

(57) **Abstract:** The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.